Business, energy, technology, markets and global industry news from Business News Today
PharmaDeviceNews
Pharma & Biotech

Why Spur Therapeutics’ gene therapy data signals a shift in Gaucher disease bone management

New FLT201 data shows potential bone disease improvement in Gaucher patients. Find out what this means for future treatment strategies.

Read More
Representative image of a modern U.S. hospital and healthcare conference setting as Ardent Health heads to the Bank of America 2026 Healthcare Conference, where investors are expected to focus on ARDT stock sentiment, hospital margins, outpatient growth, and the company’s mid-sized urban healthcare strategy.
Pharma & Biotech

Why Ardent Health’s Bank of America fireside chat could matter for hospital sector sentiment

Hospital demand is resilient, but ARDT sentiment remains cautious. Ardent Health now has to prove margins can follow access growth.

Read More
Representative image of a modern pharmaceutical manufacturing facility, highlighting how Siegfried Holding AG’s acquisition of Noramco, Extractas Biosciences and Purisys could strengthen its position in complex API production, controlled-substance manufacturing and the global CDMO supply chain.
Pharma & Biotech

Can Siegfried turn Noramco’s controlled-substance expertise into a global CDMO edge?

API security is becoming a CDMO battleground. Siegfried’s Noramco deal tests whether complex small molecules can drive the next growth phase.

Read More
Representative image of connected medical device developers reviewing wearable sensor software and health data, as Sequenex’s MedTech Innovator partnership highlights the growing role of regulatory-ready platforms in accelerating medtech startup commercialization.
Medical Devices & Diagnostics

Why Sequenex’s MedTech Innovator partnership matters for connected device startups

Medtech startups have sensors, but software can slow them down. Sequenex’s MedTech Innovator tie up targets that commercialization gap.

Read More
Representative image of image-guided breast cancer surgery planning, highlighting how Cairn Surgical’s Breast Cancer Locator trial could support more precise tumor localization, lower positive margin risk, and fewer repeat lumpectomy procedures.
Medical Devices & Diagnostics

Could Cairn Surgical’s breast cancer locator cut repeat surgeries where wires fall short?

Breast cancer surgery still struggles with missed margins. Cairn Surgical’s trial raises a sharper question for wire localization.

Read More
Representative image of unbranded pharmaceutical packaging and medicine distribution inside a modern production setting, illustrating Knoa Pharma’s launch as a public health-focused successor to Purdue Pharma and the wider debate over opioid access, oversight, and opioid crisis abatement.
Pharma & Biotech

Purdue Pharma is gone. Can Knoa Pharma turn opioid profits into public health repair?

Purdue is gone, but its medicines remain. Knoa Pharma’s public health model now faces its hardest test: trust, access, and oversight.

Read More
Representative image of a blood glucose monitoring meter showing an error warning, highlighting why Trividia Health’s TRUE METRIX correction has put diabetes device safety, glucose meter labeling, and patient risk communication under sharper scrutiny.
Medical Devices & Diagnostics

What Trividia Health’s TRUE METRIX correction reveals about diabetes device risk communication

Trividia’s TRUE METRIX correction is no routine label fix. Glucose meter safety now hinges on software, usability, and upgrade execution.

Read More
Representative image: Clinical researchers review liver disease imaging and trial data as Mirum Pharmaceuticals prepares to share VISTAS study results for volixibat in primary sclerosing cholangitis.
Pharma & Biotech

Is volixibat the next major growth lever for Mirum Pharmaceuticals beyond LIVMARLI?

Mirum has commercial momentum. VISTAS will test whether volixibat can extend that rare liver disease story into PSC.

Read More
Representative image of advanced autoimmune drug research, reflecting UCB’s proposed acquisition of Candid Therapeutics and the rising focus on T-cell engager therapies.
Pharma & Biotech

Can UCB’s $2.2bn Candid Therapeutics deal reset the future of autoimmune therapy?

UCB is paying heavily for early autoimmune science. Candid tests whether T-cell engagers can move beyond oncology into immune reset.

Read More
Representative image of a weekly contraceptive patch being assessed in a clinical setting, reflecting Viatris Inc.’s MR-100A-01 data update as the FDA review places low-dose estrogen transdermal contraception back in focus.
Pharma & Biotech

Can adhesion and lower estrogen dosing make Viatris’s contraceptive patch stand out?

Viatris has patch expertise. FDA scrutiny now decides whether lower estrogen and adhesion data can turn MR-100A-01 into a real growth lever.

Read More